Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

A gain-of-function RAC2 mutation is associated with bone-marrow hypoplasia and an autosomal dominant form of severe combined immunodeficiency.

Lagresle-Peyrou C, Olichon A, Sadek H, Roche P, Tardy C, Da Silva C, Garrigue A, Fischer A, Moshous D, Collette Y, Picard C, Casanova JL, André I, Cavazzana M.

Haematologica. 2020 Jan 9. pii: haematol.2019.230250. doi: 10.3324/haematol.2019.230250. [Epub ahead of print]

2.

Correction to A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells.

Fouqué A, Delalande O, Jean M, Castellano R, Josselin E, Malleter M, Shoji KF, Hung MD, Rampanarivo H, Collette Y, van de Weghe P, Legembre P.

J Med Chem. 2019 Oct 24;62(20):9339-9340. doi: 10.1021/acs.jmedchem.9b01578. Epub 2019 Oct 11. No abstract available.

PMID:
31603322
3.

A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells.

Arfaoui A, Rioualen C, Azzoni V, Pinna G, Finetti P, Wicinski J, Josselin E, Macario M, Castellano R, Léonard-Stumpf C, Bal A, Gros A, Lossy S, Kharrat M, Collette Y, Bertucci F, Birnbaum D, Douik H, Bidaut G, Charafe-Jauffret E, Ginestier C.

EMBO Mol Med. 2019 Oct;11(10):e9930. doi: 10.15252/emmm.201809930. Epub 2019 Sep 2.

4.

Integrated Strategy for Lead Optimization Based on Fragment Growing: The Diversity-Oriented-Target-Focused-Synthesis Approach.

Hoffer L, Voitovich YV, Raux B, Carrasco K, Muller C, Fedorov AY, Derviaux C, Amouric A, Betzi S, Horvath D, Varnek A, Collette Y, Combes S, Roche P, Morelli X.

J Med Chem. 2018 Jul 12;61(13):5719-5732. doi: 10.1021/acs.jmedchem.8b00653. Epub 2018 Jun 22.

PMID:
29883107
5.

Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.

Le Roy A, Prébet T, Castellano R, Goubard A, Riccardi F, Fauriat C, Granjeaud S, Benyamine A, Castanier C, Orlanducci F, Ben Amara A, Pont F, Fournié JJ, Collette Y, Mege JL, Vey N, Olive D.

Front Immunol. 2018 May 4;9:977. doi: 10.3389/fimmu.2018.00977. eCollection 2018.

6.

JAM-C Identifies Src Family Kinase-Activated Leukemia-Initiating Cells and Predicts Poor Prognosis in Acute Myeloid Leukemia.

De Grandis M, Bardin F, Fauriat C, Zemmour C, El-Kaoutari A, Sergé A, Granjeaud S, Pouyet L, Montersino C, Chretien AS, Mozziconacci MJ, Castellano R, Bidaut G, Boher JM, Collette Y, Mancini SJC, Vey N, Aurrand-Lions M.

Cancer Res. 2017 Dec 1;77(23):6627-6640. doi: 10.1158/0008-5472.CAN-17-1223. Epub 2017 Sep 28.

7.

Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism.

Farge T, Saland E, de Toni F, Aroua N, Hosseini M, Perry R, Bosc C, Sugita M, Stuani L, Fraisse M, Scotland S, Larrue C, Boutzen H, Féliu V, Nicolau-Travers ML, Cassant-Sourdy S, Broin N, David M, Serhan N, Sarry A, Tavitian S, Kaoma T, Vallar L, Iacovoni J, Linares LK, Montersino C, Castellano R, Griessinger E, Collette Y, Duchamp O, Barreira Y, Hirsch P, Palama T, Gales L, Delhommeau F, Garmy-Susini BH, Portais JC, Vergez F, Selak M, Danet-Desnoyers G, Carroll M, Récher C, Sarry JE.

Cancer Discov. 2017 Jul;7(7):716-735. doi: 10.1158/2159-8290.CD-16-0441. Epub 2017 Apr 17.

8.

Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer.

M-Rabet M, Cabaud O, Josselin E, Finetti P, Castellano R, Farina A, Agavnian-Couquiaud E, Saviane G, Collette Y, Viens P, Gonçalves A, Ginestier C, Charafe-Jauffret E, Birnbaum D, Olive D, Bertucci F, Lopez M.

Ann Oncol. 2017 Apr 1;28(4):769-776. doi: 10.1093/annonc/mdw678.

9.

BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemia.

Benyamine A, Le Roy A, Mamessier E, Gertner-Dardenne J, Castanier C, Orlanducci F, Pouyet L, Goubard A, Collette Y, Vey N, Scotet E, Castellano R, Olive D.

Oncoimmunology. 2016 Apr 25;5(10):e1146843. eCollection 2016.

10.

Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy.

Moschoi R, Imbert V, Nebout M, Chiche J, Mary D, Prebet T, Saland E, Castellano R, Pouyet L, Collette Y, Vey N, Chabannon C, Recher C, Sarry JE, Alcor D, Peyron JF, Griessinger E.

Blood. 2016 Jul 14;128(2):253-64. doi: 10.1182/blood-2015-07-655860. Epub 2016 Jun 2.

PMID:
27257182
11.

Protein-Protein Interaction Inhibition (2P2I)-Oriented Chemical Library Accelerates Hit Discovery.

Milhas S, Raux B, Betzi S, Derviaux C, Roche P, Restouin A, Basse MJ, Rebuffet E, Lugari A, Badol M, Kashyap R, Lissitzky JC, Eydoux C, Hamon V, Gourdel ME, Combes S, Zimmermann P, Aurrand-Lions M, Roux T, Rogers C, Müller S, Knapp S, Trinquet E, Collette Y, Guillemot JC, Morelli X.

ACS Chem Biol. 2016 Aug 19;11(8):2140-8. doi: 10.1021/acschembio.6b00286. Epub 2016 Jun 3.

PMID:
27219844
12.

Identification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2-JNK signalling in breast cancer.

Puvirajesinghe TM, Bertucci F, Jain A, Scerbo P, Belotti E, Audebert S, Sebbagh M, Lopez M, Brech A, Finetti P, Charafe-Jauffret E, Chaffanet M, Castellano R, Restouin A, Marchetto S, Collette Y, Gonçalvès A, Macara I, Birnbaum D, Kodjabachian L, Johansen T, Borg JP.

Nat Commun. 2016 Jan 12;7:10318. doi: 10.1038/ncomms10318.

13.

Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins.

Raux B, Voitovich Y, Derviaux C, Lugari A, Rebuffet E, Milhas S, Priet S, Roux T, Trinquet E, Guillemot JC, Knapp S, Brunel JM, Fedorov AY, Collette Y, Roche P, Betzi S, Combes S, Morelli X.

J Med Chem. 2016 Feb 25;59(4):1634-41. doi: 10.1021/acs.jmedchem.5b01708. Epub 2016 Jan 6.

PMID:
26735842
14.

A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells.

Fouqué A, Delalande O, Jean M, Castellano R, Josselin E, Malleter M, Shoji KF, Hung MD, Rampanarivo H, Collette Y, van de Weghe P, Legembre P.

J Med Chem. 2015 Aug 27;58(16):6559-73. doi: 10.1021/acs.jmedchem.5b00991. Epub 2015 Aug 14. Erratum in: J Med Chem. 2019 Oct 24;62(20):9339-9340.

PMID:
26237138
15.

A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia.

Saland E, Boutzen H, Castellano R, Pouyet L, Griessinger E, Larrue C, de Toni F, Scotland S, David M, Danet-Desnoyers G, Vergez F, Barreira Y, Collette Y, Récher C, Sarry JE.

Blood Cancer J. 2015 Mar 20;5:e297. doi: 10.1038/bcj.2015.19.

16.

Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia.

Collette Y, Prébet T, Goubard A, Adélaïde J, Castellano R, Carbuccia N, Garnier S, Guille A, Arnoulet C, Charbonier A, Mozziconacci MJ, Birnbaum D, Chaffanet M, Vey N.

Blood Cancer J. 2015 Mar 13;5:e292. doi: 10.1038/bcj.2015.13. No abstract available.

17.

Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia, T-ALL.

Loosveld M, Castellano R, Gon S, Goubard A, Crouzet T, Pouyet L, Prebet T, Vey N, Nadel B, Collette Y, Payet-Bornet D.

Oncotarget. 2014 May 30;5(10):3168-72.

18.

Context-selective death of acute myeloid leukemia cells triggered by the novel hybrid retinoid-HDAC inhibitor MC2392.

De Bellis F, Carafa V, Conte M, Rotili D, Petraglia F, Matarese F, Françoijs KJ, Ablain J, Valente S, Castellano R, Goubard A, Collette Y, Mandoli A, Martens JH, de Thé H, Nebbioso A, Mai A, Stunnenberg HG, Altucci L.

Cancer Res. 2014 Apr 15;74(8):2328-39. doi: 10.1158/0008-5472.CAN-13-2568. Epub 2014 Feb 24.

19.

The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression.

Salvador MA, Wicinski J, Cabaud O, Toiron Y, Finetti P, Josselin E, Lelièvre H, Kraus-Berthier L, Depil S, Bertucci F, Collette Y, Birnbaum D, Charafe-Jauffret E, Ginestier C.

Clin Cancer Res. 2013 Dec 1;19(23):6520-31. doi: 10.1158/1078-0432.CCR-13-0877. Epub 2013 Oct 18.

20.

CD95L cell surface cleavage triggers a prometastatic signaling pathway in triple-negative breast cancer.

Malleter M, Tauzin S, Bessede A, Castellano R, Goubard A, Godey F, Levêque J, Jézéquel P, Campion L, Campone M, Ducret T, MacGrogan G, Debure L, Collette Y, Vacher P, Legembre P.

Cancer Res. 2013 Nov 15;73(22):6711-21. doi: 10.1158/0008-5472.CAN-13-1794. Epub 2013 Sep 26.

21.

Stereoselective synthesis of original spirolactams displaying promising folded structures.

Chaubet G, Coursindel T, Morelli X, Betzi S, Roche P, Guari Y, Lebrun A, Toupet L, Collette Y, Parrot I, Martinez J.

Org Biomol Chem. 2013 Jul 28;11(28):4719-26. doi: 10.1039/c3ob40643a. Epub 2013 Jun 13.

22.

Tumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancer.

Mezil L, Berruyer-Pouyet C, Cabaud O, Josselin E, Combes S, Brunel JM, Viens P, Collette Y, Birnbaum D, Lopez M.

PLoS One. 2012;7(9):e43409. doi: 10.1371/journal.pone.0043409. Epub 2012 Sep 18.

23.

Structural recognition mechanisms between human Src homology domain 3 (SH3) and ALG-2-interacting protein X (Alix).

Shi X, Betzi S, Lugari A, Opi S, Restouin A, Parrot I, Martinez J, Zimmermann P, Lecine P, Huang M, Arold ST, Collette Y, Morelli X.

FEBS Lett. 2012 Jun 21;586(13):1759-64. doi: 10.1016/j.febslet.2012.05.017. Epub 2012 May 26.

24.

Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts.

Gertner-Dardenne J, Castellano R, Mamessier E, Garbit S, Kochbati E, Etienne A, Charbonnier A, Collette Y, Vey N, Olive D.

J Immunol. 2012 May 1;188(9):4701-8. doi: 10.4049/jimmunol.1103710. Epub 2012 Mar 30.

25.

Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy.

Veuillen C, Aurran-Schleinitz T, Castellano R, Rey J, Mallet F, Orlanducci F, Pouyet L, Just-Landi S, Coso D, Ivanov V, Carcopino X, Bouabdallah R, Collette Y, Fauriat C, Olive D.

J Clin Immunol. 2012 Jun;32(3):632-46. doi: 10.1007/s10875-011-9624-5. Epub 2012 Feb 9.

PMID:
22318393
26.

Design of N-substituted amino caproic hydroxamic acid histone deacetylase inhibitors reveal an essential role for cap atomic composition.

Brunel JM, Salmi-Smail C, Restouin A, Prebet T, Vey N, Collette Y.

Anticancer Agents Med Chem. 2012 Sep;12(7):801-6.

PMID:
22263799
27.

A specific protein disorder catalyzer of HIV-1 Nef.

Lugari A, Breuer S, Coursindel T, Opi S, Restouin A, Shi X, Nazabal A, Torbett BE, Martinez J, Collette Y, Parrot I, Arold ST, Morelli X.

Bioorg Med Chem. 2011 Dec 15;19(24):7401-6. doi: 10.1016/j.bmc.2011.10.051. Epub 2011 Oct 20.

PMID:
22061824
28.

Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1.

Chaib H, Nebbioso A, Prebet T, Castellano R, Garbit S, Restouin A, Vey N, Altucci L, Collette Y.

Leukemia. 2012 Apr;26(4):662-74. doi: 10.1038/leu.2011.271. Epub 2011 Oct 7.

PMID:
21979880
29.

[Histone methyltransferases: a new class of therapeutic targets in cancer treatment?].

Chaib H, Prébet T, Vey N, Collette Y.

Med Sci (Paris). 2011 Aug-Sep;27(8-9):725-32. doi: 10.1051/medsci/2011278014. Epub 2011 Aug 31. Review. French.

30.

Identification and biophysical assessment of the molecular recognition mechanisms between the human haemopoietic cell kinase Src homology domain 3 and ALG-2-interacting protein X.

Shi X, Opi S, Lugari A, Restouin A, Coursindel T, Parrot I, Perez J, Madore E, Zimmermann P, Corbeil J, Huang M, Arold ST, Collette Y, Morelli X.

Biochem J. 2010 Oct 1;431(1):93-102. doi: 10.1042/BJ20100314.

PMID:
20670214
31.

Stereoselective ring contraction of 2,5-diketopiperazines: An innovative approach to the synthesis of promising bioactive 5-membered scaffolds.

Coursindel T, Restouin A, Dewynter G, Martinez J, Collette Y, Parrot I.

Bioorg Chem. 2010 Oct;38(5):210-7. doi: 10.1016/j.bioorg.2010.05.002. Epub 2010 May 25.

PMID:
20609458
32.

Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.

Salmi-Smail C, Fabre A, Dequiedt F, Restouin A, Castellano R, Garbit S, Roche P, Morelli X, Brunel JM, Collette Y.

J Med Chem. 2010 Apr 22;53(8):3038-47. doi: 10.1021/jm901358y.

33.

A simplified, 96-well-adapted, ATP luminescence-based motility assay.

Restouin A, Aresta S, Prébet T, Borg JP, Badache A, Collette Y.

Biotechniques. 2009 Oct;47(4):871-5. doi: 10.2144/000113250.

34.

Alternative splicing modulates autoinhibition and SH3 accessibility in the Src kinase Fyn.

Brignatz C, Paronetto MP, Opi S, Cappellari M, Audebert S, Feuillet V, Bismuth G, Roche S, Arold ST, Sette C, Collette Y.

Mol Cell Biol. 2009 Dec;29(24):6438-48. doi: 10.1128/MCB.00398-09. Epub 2009 Oct 5.

35.

Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions.

Vire B, de Walque S, Restouin A, Olive D, Van Lint C, Collette Y.

PLoS One. 2009 Sep 17;4(9):e7085. doi: 10.1371/journal.pone.0007085.

36.

Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection.

Reuse S, Calao M, Kabeya K, Guiguen A, Gatot JS, Quivy V, Vanhulle C, Lamine A, Vaira D, Demonte D, Martinelli V, Veithen E, Cherrier T, Avettand V, Poutrel S, Piette J, de Launoit Y, Moutschen M, Burny A, Rouzioux C, De Wit S, Herbein G, Rohr O, Collette Y, Lambotte O, Clumeck N, Van Lint C.

PLoS One. 2009 Jun 30;4(6):e6093. doi: 10.1371/journal.pone.0006093.

37.

[Pathogenic agents and cancer].

Olive D, Rey J, Collette Y, Carcopino X, Hirsch I.

Med Mal Infect. 2008 Jun;38 Suppl 2:S45-6. doi: 10.1016/S0399-077X(08)72987-1. French. No abstract available.

PMID:
18598866
38.

Amine-guanidine switch: a promising approach to improve DNA binding and antiproliferative activities.

Ohara K, Smietana M, Restouin A, Mollard S, Borg JP, Collette Y, Vasseur JJ.

J Med Chem. 2007 Dec 27;50(26):6465-75. Epub 2007 Dec 4.

PMID:
18052116
39.

Protein protein interaction inhibition (2P2I) combining high throughput and virtual screening: Application to the HIV-1 Nef protein.

Betzi S, Restouin A, Opi S, Arold ST, Parrot I, Guerlesquin F, Morelli X, Collette Y.

Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19256-61. Epub 2007 Nov 27.

40.

Signaling-dependent immobilization of acylated proteins in the inner monolayer of the plasma membrane.

Corbett-Nelson EF, Mason D, Marshall JG, Collette Y, Grinstein S.

J Cell Biol. 2006 Jul 17;174(2):255-65. Epub 2006 Jul 10.

41.
42.

A role for the neuronal protein collapsin response mediator protein 2 in T lymphocyte polarization and migration.

Vincent P, Collette Y, Marignier R, Vuaillat C, Rogemond V, Davoust N, Malcus C, Cavagna S, Gessain A, Machuca-Gayet I, Belin MF, Quach T, Giraudon P.

J Immunol. 2005 Dec 1;175(11):7650-60.

43.

Evidences for ubiquitination and intracellular trafficking of LAT, the linker of activated T cells.

Brignatz C, Restouin A, Bonello G, Olive D, Collette Y.

Biochim Biophys Acta. 2005 Dec 15;1746(2):108-15. Epub 2005 Oct 4.

44.

Transcription factor binding sites in the pol gene intragenic regulatory region of HIV-1 are important for virus infectivity.

Goffin V, Demonté D, Vanhulle C, de Walque S, de Launoit Y, Burny A, Collette Y, Van Lint C.

Nucleic Acids Res. 2005 Aug 1;33(13):4285-310. Print 2005.

45.
46.

Frontline: Characterization of BT3 molecules belonging to the B7 family expressed on immune cells.

Compte E, Pontarotti P, Collette Y, Lopez M, Olive D.

Eur J Immunol. 2004 Aug;34(8):2089-99.

47.

Dynamic recruitment of the adaptor protein LAT: LAT exists in two distinct intracellular pools and controls its own recruitment.

Bonello G, Blanchard N, Montoya MC, Aguado E, Langlet C, He HT, Nunez-Cruz S, Malissen M, Sanchez-Madrid F, Olive D, Hivroz C, Collette Y.

J Cell Sci. 2004 Mar 1;117(Pt 7):1009-16.

48.

Functional interaction of RasGAP-binding proteins Dok-1 and Dok-2 with the Tec protein tyrosine kinase.

Gérard A, Favre C, Garçon F, Némorin JG, Duplay P, Pastor S, Collette Y, Olive D, Nunès JA.

Oncogene. 2004 Feb 26;23(8):1594-8.

PMID:
14647425
49.

Potentiation of tumor necrosis factor-induced NF-kappa B activation by deacetylase inhibitors is associated with a delayed cytoplasmic reappearance of I kappa B alpha.

Adam E, Quivy V, Bex F, Chariot A, Collette Y, Vanhulle C, Schoonbroodt S, Goffin V, Nguyên TL, Gloire G, Carrard G, Friguet B, De Launoit Y, Burny A, Bours V, Piette J, Van Lint C.

Mol Cell Biol. 2003 Sep;23(17):6200-9. Erratum in: Mol Cell Biol. 2004 Aug;24(15):6890.

50.

A co-evolution perspective of the TNFSF and TNFRSF families in the immune system.

Collette Y, Gilles A, Pontarotti P, Olive D.

Trends Immunol. 2003 Jul;24(7):387-94. Review.

PMID:
12860530

Supplemental Content

Loading ...
Support Center